Improvement of dissolution of poorly soluble glimepiride by loading on two types of mesoporous silica carriers

Enlarged pore of worm mesoporous silica nanoparticles improves anti-inflammatory drug absorption

Searching for an effective pore-enlarging agent to form mesoporous silica nanoparticles (MSN) with a creative surface frame is of great importance. Herein, several polymers were attempted to be pore-enlarging agents to form seven types of worm mesoporous silica nanoparticles (W-MSN) and analgesic indometacin that exerted functions on inflammatory diseases (breast disease, arthrophlogosis, etc.) was studied to enhance its delivery efficiency. The porous morphology differences between MSN and W-MSN were that MSN had independent mesopores while the enlarged mesopores of W-MSN were interrelated and shaped as a worm. Among all these W-MSN, WG-MSN templated by hydroxypropyl cellulose acetate succinate HG with the highest drug-loading capacity (24.78%), shortest loading time (10 h), drug dissolution improvement of almost 4 times compared to that of the raw drug, and highest bioavailability (5.48 times higher than that of raw drug and 1.52 times higher than that of MSN) was an outstanding drug carrier and can shoulder the mission to deliver drugs with high efficiency.

Doxorubicin and Quercetin Double Loading in Modified MCM-41 Lowered Cardiotoxicity in H9c2 Cardioblast Cells In Vitro

BACKGROUND

One of the therapeutic limitations of the use of doxorubicin (DOX) as an anticancer drug is its cardiotoxicity. Its hydrophilicity also causes difficulties in achieving sustained release. The simultaneous delivery with the well-known natural antioxidant quercetin could ameliorate its cardiotoxicity. Thus, the main aim of this work is to study the potential of carboxylated and non-carboxylated mesoporous silica MCM-41 nanoparticles for double loading of the hydrophilic doxorubicin hydrochloride and hydrophobic quercetin (Q) in one nanocarrier with a modified release pattern to reduce the cardiotoxic side effects of doxorubicin in vitro.

METHODS

The methods included the modification of MCM-41, single and double loading of modified and non-modified MCM-41, physicochemical characterization, in vitro release tests and kinetic study, and in vitro cell viability studies.

RESULTS

Doxorubicin and quercetin were successfully double-loaded with encapsulation efficiency (EE) of 43 ± 4.1% and 37 ± 4.5%, respectively, in native MCM-41. The post-synthetic carboxylation led to 49 ± 4.3% EE (DOX) and 36 ± 4.0% (Q) and double lowering of the cardiotoxicity on H9c2 (IC50 = 5.96 µm). Sustained release profiles over 72 h were achieved.

CONCLUSIONS

A successful procedure was proposed for the efficient double loading of a hydrophilic drug and a hydrophobic drug. The carboxy-modified double-loaded nanosystems demonstrate a decreased in vitro cardiotoxicity of doxorubicin and can be considered as a potential chemotherapeutic formulation.

A Study of 5-Fluorouracil Desorption from Mesoporous Silica by RP-UHPLC

In cancer treatment, the safe delivery of the drug to the target tissue is an important task. 5-fluorouracil (5-FU), the well-known anticancer drug, was encapsulated into the pores of unmodified mesoporous silica SBA-15, as well as silica modified with 3-aminopropyl and cyclohexyl groups. The drug release studies were performed in two different media, in a simulated gastric fluid (pH = 2) and in a simulated body fluid (pH = 7) by RP-UHPLC. The simple and rapid RP-UHPLC method for quantitative determination of 5-fluorouracil released from unmodified and modified mesoporous silica SBA-15 was established on ODS Hypersil C18 column (150 × 4.6 mm, 5 µm) eluted with mobile phase consisted of methanol: phosphate buffer in volume ratio of 3:97 (v/v). Separation was achieved by isocratic elution. The flow rate was kept at 1 mL/min, the injection volume was set at 20 µL and the column oven temperature was maintained at 25 °C. The effluent was monitored at 268 nm. This paper provides information about the quantitative determination of the released 5-FU from silica. It was found out that larger amount of the drug was released in neutral pH in comparison with the acidic medium. In addition, surface functionalisation of silica SBA-15 influences the release properties of the drug.